Tacrolimus (FK 506) overdose: A report of five cases

Journal of Toxicology - Clinical Toxicology

Volumn 35, Issue 4, 1997, Pages 395-399

  Mrvos, Rita ^a   Hodgman, Michael ^b   Krenzelok, Edward P ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; CREATININE; TACROLIMUS;

ACUTE TOXICITY; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG OVERDOSE; FEMALE; HUMAN; INFANT; KIDNEY FUNCTION; MALE; ORAL DRUG ADMINISTRATION; SYMPTOMATOLOGY;

FUNGI; STREPTOMYCES TSUKUBAENSIS;

EID: 0030851295     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.3109/15563659709043372     Document Type: Article

References (28)

1. McCauley J, Fung J, Jain A, Todo S, Starzl TE. The effects of FK 506 on renal function after liver transplantation. Transplant Proc 1990;22:17S-20S.
2. Thomson AW. FK 506: Profile of an important new immunosuppressant. Transplant Rev 1990;4:1-13.
3. Goto T, Kino T, Hatanaka H, et al. Discovery of FK 506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987;19: 4S-8S.
4. Fung J, Alessiani M, Abu-Elmagd K, et al. Adverse effects associated with the use of FK 506. Transplant Proc 1991;23:3105-3108.
5. Jain AB, Fung R, Venkataramanan S, Todo S, Alessiani M, Starzl TE. FK 506 dosage in human organ transplantation. Transplant Proc 1990;22:23-24.
6. Venkataramanan R, Jain A, Warty VS, et al. Pharmacokinetics of FK 506 in transplant patients. Transplant Proc 1991;23:2736-2740.
7. Hooks MA. Tacrolimus, a new immunosuppressant - a review of the literature. Ann Pharmacother 1994;28: 501-511.
8. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995;57:281-290.
9. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK 506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-761.
10. Yasuhara M, Hashida T, Toraguchi M, et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc 1995;27:1108-1110.
11. Assan R, Fredji G, Larger E, Feutren G, Bismuth H. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity. Diabete Metab 1994;20:49-52.
12. Schwartz M, Holst B, Facklam D, Buell D. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. Transplant Proc 1995;27:1107.
13. Warty V, Zuckerman S, Venkataramanan R, et al. Tacrolimus analysis: a comparison of different methods and matrices. Ther Drug Monit 1995;17: 159-167.
14. Alessiani M, Cillo U, Fung JJ, et al. Adverse effects of FK 506 overdosage after liver transplantation. Transplant Proc 1993;25:628-634.
15. Atkinson P, Joubert G, Barron A, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995;345:894-896.
16. Hibi S, Misawa A, Tamai M, et al. Severe rhabdomyolysis associated with tacrolimus. Lancet 1995;346:702.
17. Dollinger MM, Plevris JN, Chauhan A, MacGilchrist AJ, Finlayson MD, Hayes PC. Tacrolimus and cardiotoxicity in adult liver transplant recipients. Lancet 1995;346:507.
18. Fisher A, Schwartz M, Mor E, et al. Gastrointestinal toxicity associated with FK 506 in liver transplant recipients. Transplant Proc 1994;26:3106-3107.
19. Fisher A, Mor A, Hytiroglou P, et al. FK 506 hepatotoxicity in liver allograft recipients. Transplantation 1995;59:1631-1632.
20. Platz KP, Mueller AR, Blumhardt G. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK 506. Transplantation 1994;58:170-178.
21. Porayko MK, Textor SC, Krom RA, et al. Nephrotoxic effects of primary immunosuppression with FK 506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc 1994;69:105-111.
22. Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. Transplant Proc 1991;23:3153-3155.
23. Sumpio BE, Phan S. Nephrotoxic potential of FK 506. Transplant Proc 1991;23:2789-2790.
24. Nielsen FT, Leyssac PP, Kemp E, Starklint H, Dieperink H. Nephrotoxicity of FK 506: a preliminary study on comparative aspects of FK 506 and cyclosporine nephrotoxicity. Transplant Proc 1994;26:3104-3105.
25. Andoh TF, Burdmann EA, Lindsley J, Houghton DC, Bennett WM. Functional and structural characteristics of experimental FK 506 nephrotoxicity. Clin Exp Pharmacol Physiol 1995;22:646-654.
26. Wijdicks EF, Wiesner RH, Dahlke LJ, Drom RA. FK 506-induced neurotoxicity in liver transplantation. Ann Neurol 1994;35:498-501.
27. Bronster DJ, Yonover P, Stein J, Scelsa SN, Miller CM, Sheiner PA. Demyelinating sensorimotor polyneuropathy after administration of FK 506. Transplantation 1995;59:1066-1068.
28. Ayres RC, Dousset B, Wixon S, Buckels JA, McMaster P, Mayer AD. Peripheral neurotoxicity with tacrolimus. Lancet 1994;343:862-863.